tradingkey.logo

Guardant Health Inc

GH
View Detailed Chart
101.850USD
+3.490+3.55%
Close 02/06, 16:00ETQuotes delayed by 15 min
12.73BMarket Cap
LossP/E TTM

Guardant Health Inc

101.850
+3.490+3.55%
Intraday
1m
30m
1h
D
W
M
D

Today

+3.55%

5 Days

-10.69%

1 Month

-9.33%

6 Months

+128.41%

Year to Date

-0.28%

1 Year

+120.98%

View Detailed Chart

TradingKey Stock Score of Guardant Health Inc

Currency: USD Updated: 2026-02-06

Key Insights

Guardant Health Inc's fundamentals are relatively healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 47 out of 205 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 121.52.In the medium term, the stock price is expected to remain stable.Despite a weak stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Guardant Health Inc's Score

Industry at a Glance

Industry Ranking
47 / 205
Overall Ranking
137 / 4521
Industry
Healthcare Equipment & Supplies

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score
Previous score

Media Coverage

Last 24 hours
Coverage Level

Very Low
Very High
Neutral

Guardant Health Inc Highlights

StrengthsRisks
Guardant Health, Inc. is a precision oncology company focused on guarding wellness and giving every person more time free from cancer. It provides critical insights into what drives disease through its advanced blood and tissue tests, real-world data, and artificial intelligence (AI) analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and helping doctors select the treatment for patients with advanced cancer. For patients with advanced-stage cancer, it has developed Guardant360 laboratory developed test (LDT), and Guardant360 CDx test, a comprehensive liquid biopsy test to provide tumor mutation profiling with solid tumors and to be used as a companion diagnostic in connection with non-small cell lung cancer (NSCLC), and breast cancer. It offers other tests, including Guardant360 Tissue test, Guardant Reveal blood test, Guardant360 Response blood test and others.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 64.39% year-on-year.
Undervalued
The company’s latest PE is -31.70, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 125.58M shares, decreasing 11.91% quarter-over-quarter.
Held by Ray Dalio
Star Investor Ray Dalio holds 4.01K shares of this stock.

Analyst Rating

Based on 24 analysts
Buy
Current Rating
121.520
Target Price
+23.55%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Guardant Health Inc News

More news coming soon, stay tuned...

Financial Indicators

EPS

Relevant data have not been disclosed by the company yet.

Total revenue

Relevant data have not been disclosed by the company yet.

Guardant Health Inc Info

Guardant Health, Inc. is a precision oncology company focused on guarding wellness and giving every person more time free from cancer. It provides critical insights into what drives disease through its advanced blood and tissue tests, real-world data, and artificial intelligence (AI) analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and helping doctors select the treatment for patients with advanced cancer. For patients with advanced-stage cancer, it has developed Guardant360 laboratory developed test (LDT), and Guardant360 CDx test, a comprehensive liquid biopsy test to provide tumor mutation profiling with solid tumors and to be used as a companion diagnostic in connection with non-small cell lung cancer (NSCLC), and breast cancer. It offers other tests, including Guardant360 Tissue test, Guardant Reveal blood test, Guardant360 Response blood test and others.
Ticker SymbolGH
CompanyGuardant Health Inc
CEOTalasaz (Amirali)
Websitehttps://guardanthealth.com/
KeyAI